Advances in hypertrophic cardiomyopathy: What the cardiologist needs to know

Abstract

Hypertrophic cardiomyopathy (HCM) is known as the most common genetic heart disease, characterized by otherwise unexplained left ventricular (LV) hypertrophy. In spite of major advances in whole genome sequence techniques, it is still not possible to identify the causal mutation in approximately half of HCM patients. Consequently, a new HCM concept, "beyond the sarcomere" is being developed, supported by data from recent HCM registries which reveal two distinct HCM subgroups: sarcomere positive HCM subgroup and nonfamilial HCM subgroup. Sarcomere positive HCM patients tend to be younger age at diagnosis, have fewer co-morbidities, present more often with reverse septal morphology, more myocardial fibrosis, less LV outflow tract obstruction, and a worse prognosis when compared to nonfamilial HCM patients. These subgroups, with different molecular basis, phenotypes and clinical profiles, will likely require specific management strategies. Important research advances have also been made concerning diagnosis, sudden cardiac death stratification and therapy. In this article, we seek to review recent relevant knowledge, summarizing the advances in this complex and heterogeneous disease.

Keywords: Atrial fibrillation; Fibrilhação auricular; Heart failure; Hypertrophic cardiomyopathy; Insuficiência cardíaca; Miocardiopatia hipertrófica; Morte súbita cardíaca; Nonfamilial; Não familiar; Prognosis; Prognóstico; Sarcomere positive; Sarcomérica-positiva; Sudden cardiac death; Tratamento; Treatment.